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Abstract
Background: Both urinary bilharziasis and urothelial neoplasia are associated with increased
production of tissue carcinoembryonic antigen (CEA).
Patients and methods: Urine and serum CEA were determined in 43 patients with urinary
bladder carcinoma including 22 post bilharzial and 21 nonbiharzial cases, in addition to 10 normal
control cases.
Results: A significant increase was detected in both urine and serum CEA levels with bladder
carcinoma compared to control cases. Urinary CEA was significantly elevated in 86% of bilharzial,
versus 62% in nonbilharzial bladder carcinoma. Only 10.5% of control cases had urinary CEA
elevation. The mean urinary CEA in bilharzial, was higher than that of nonbilharzial carcinoma, but
the difference was not statistically significant. There was a definite relationship between urine CEA
and the stage of malignancy; the higher the stage, the higher the level of urine CEA. No relationship
could be detected between the stage of malignancy and serum CEA, or between the grades of
malignancy and urine or serum CEA levels.
Conclusion: Urinary CEA is more useful than serum CEA in the early detection of urotherlial
carcinoma particularly if provoked by bilharziasis. Its level is also correlated with the tumor stage.
Background
Carcinoembryonic antigen (CEA) a specific product of
neoplasia derived from the endoderm and is supposed to
have a potential value in screening, diagnosis and follow-
up of patients suspected of having urothelial carcinoma
[1]. It has also been detected in other types of normal
human tissue including prostate, uterus and spleen. This
aroused fears of false positive results and of compromis-
ing specificity if further enhancement of sensitivity was
tried [2]. Urinary CEA measurement and cytological
examination are two noninvasive procedures that were
compared and found to yield similar frequencies of posi-
tivity. Simultaneous performance of these two tests
increased the yield of positive results to 86% [3]. It was
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also suggested that assay of urinary CEA might provide an
alternative to urinary cytology for industrial screening of
high-risk population. In hospital practice, it was thought
to be useful alongside cytology and cystoscopy in primary
diagnosis and routine follow-up of patients with urothe-
lial tumors after treatment to detect early recurrences. It
was also found to add to the information of T classifica-
tion [4,5]. The finding that T1 and in situ carcinoma can
yield raised values of CEA is of potential importance as it
is this group of tumors which is difficult to detect by uri-
nary exfoliative cytology [6].
Urinary CEA was first suggested to be particularly helpful
to evaluate urothelial dysplasia [7] and in patients with
bilharzial chronic cystitis it may affords a valuable screen-
ing test for premalignant lesions and malignant transfor-
mation [8,9].
Raised serum CEA was recorded in association with inva-
sive tumors or the presence of metastatic disease [10,11].
With regards CEA tissue level, it was found to be higher in
malignant vesical urothelium than in the control group,
concentrations were much higher with infiltrating tumors
[12]. Normalization of CEA level in follow-up of treated
cases points to successful management [13]. On the other
hand, local recurrence or multiple metastases were found
to be associated with elevated CEA [14].
Bilharzial carcinoma of the urinary bladder was found to
represent a distinct clinico-pathological entity different
from nonbilharzial carcinoma [15]. The aim of this study
is to throw light on the value of urinary and serum CEA in
the diagnosis of carcinoma of the urinary bladder and to
see if there is any difference between bilharzial and non-
bilharzial carcinoma as regards production of CEA, a new
point not handled before.
Patients and methods
This study was conducted at Kasr EI-Aini University Hos-
pitals, Cairo/Egypt from April 2002 through April 2005.
Forty three patients having proven carcinoma of the uri-
nary bladder beside 10 control cases were enrolled in the
study and categorized into three groups. Group I included
22 patients having bilharzial carcinoma; group II included
21 patients having nonbilharzial carcinoma while group
III consisted of 10 normal controls with no infection or
malignancy of the urinary tract or malignancy elsewhere.
Radical cystectomy was done to patients of the first two
groups. Transuretheral resection was not attempted even
in early lesions due to the prevalence of multicentricity in
bilharzial cases and to standardize the treatment proce-
dure.
For every case, urine and serum CEA were measured.
Patients showing evidence of acute urinary tract infection
were excluded. Samples of 10 ml of midstream morning
urine were collected. Samples with 5 pus cells or more/
HPF were discarded. Five ml of blood were obtained from
fasting individuals after at least 6 hours of stopping smok-
ing. No additives or preservatives were necessary to main-
tain the integrity of the specimens. Grossly hemolysed
samples were discarded. CEA was measured in both urine
and serum by monoclonal enzyme immunoassay (EIA)
method using a commercially available kit from Abbott.
The normal adult range by this method is less than 3 ng/
ml in serum and less than 30 ng/ml in urine. Insignificant
minimal elevations are found in heavy smokers.
For patients with carcinoma of the urinary bladder, the
following was done: a detailed clinical historywas taken
and patients with a positive history of bilharziasis were
excluded from group II, but this was not sufficient to put
them in group I. Secondary bacterial infections were
excluded before enrollment as it may affect urinary CEA
values. No evidence that bilharziasis alone (in the absence
of frank premalignant lesions or cellular dysplasia) has
such effect [8]. Clinico-pathological examination
included bimanual examination to assess operability par-
ticularly in bilharzial carcinoma where the mobility (not
the size) is important. Staging was done according to the
TNM system of UICC [16] for non-bilharzial cases it was
done by CT scans and confirmed postoperatively on the
resected specimens. Cystoscopic examination and biopsy
were performed. Radical cystectomy was done for all cases
and the specimens were examined for type and grade of
malignancy, pathological staging and the presence or
absence of associated bilharzial cystitis.
Results
There was a definite relationship between the stage of
malignancy and the level of urine CEA, the higher the
stage the higher the level of urine CEA. There was no rela-
tionship between the stage of malignancy and the level of
serum CEA or between the grade of malignancy and the
levels of both urine and serum CEA. The evidence was
observed using correlation coefficient (r). Table 1 shows
the relation of urine and serum CEA levels with type,
grade and stage in bilharzial carcinoma. The relation is
direct with correlation coefficient 0.131 at p  = 0.0236.
Table 2 shows same relation in non-bilharzial cases (cor-
relation coefficient is -0.25 at p = 0.0007). In control cases
correlation coefficient was 0.60 at p = 0.065. Finally Table
3 compares the percentage of cases with high levels of
urine and serum CEA in the three groups. Table 4 show
percentage of cases having urine CEA above 10 ng/ml and
serum CEA above 5 ng/ml.
Discussion
Since CEA is present in the normal urothelium, destruc-
tion and regeneration of urothelial cells due to tumor orWorld Journal of Surgical Oncology 2007, 5:4 http://www.wjso.com/content/5/1/4
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inflammation might release CEA into the urine [17]. It
was suggested by some authors that elevated urinary CEA
values, once infection is excluded, are specific to urothe-
lial carcinoma, as the levels are normal in association with
nonurothelial tumors such as hypernephroma, prostatic
and colorectal carcinoma [16]. Even if the plasma levels
are raised, the urinary levels rise only when such tumors
involve the urinary tract by infiltration. Urinary CEA like
activity was found to be increased in 61% of patients with
transitional cell carcinoma of the bladder [3]. On the
other hand, serial measurement of serum CEA was noted
to judge response of advanced urothelial tumors to chem-
otherapy [18]. In this series, after exclusion of acute infec-
tion, urine CEA levels were raised in 86% of patients with
bilharzial carcinoma and in 62% of patients with nonbil-
harzial carcinoma of the urinary bladder. There was also a
significant difference between urine CEA in cancer
patients and in the controls.
Morning samples of urine were shown to be more inform-
ative because of the benefit of overnight exposure of urine
to the tumor [11]. On the other hand, 24 hour urinary
CEA was advised to be measured, as it was shown to be
more informative being elevated in 81% of patients with
active tumors [7]. In this series, CEA was measured in the
morning samples of urine only.
Urinary infection was found to spoil the use of urinary
CEA as a diagnostic procedure [11]. The simple presence
of bacteria in the urine irrespective of their identity or
number has no influence on urinary CEA [19]. It is the
inflammation of the urothelium that is responsible for the
production and release of CEA. Therefore, only in the
presence of symptoms and signs, and in the presence of
pyuria, urinary tract infection is considered to exist. Infec-
tion was considered to be present if 5 leukocytes/HPF or
more exist in the urine [17]. On the other hand, the effect
of infection can largely be eliminated by routine use of
midstream specimens of urine and its examination for pus
cells and organisms [1]. However, in this series patients
showing symptoms and signs of acute urinary tract infec-
tion were excluded from the study. Midstream samples of
urine were collected and examined for pus cells.
Serum CEA levels were found by some investigators to be
of little value in the diagnosis of transitional cell carci-
noma [3]. In addition, there was no correlation between
serum and urinary CEA values. On the other hand, serum
and urine CEA were found by other investigators to have
less than enough of the diagnostic accuracy required for
clinical diagnosis of urothelial cancer [20]. In this series,
there were many patients with raised urinary CEA levels
while serum CEA levels were within normal, but in two
Table 1: CEA in urine and serum, histopathological type, grade of malignancy and pathological stage of bilharzial carcinoma of the 
urinary bladder.
Case no Urine CEA Serum CEA Histological type Grade of malignancy Pathological staging
1 55 5 Squamous cell II P2
2 47 - Squamous cell I P2
3 9 17 Squamus cell I P1
4 72 - Squamous cell I P2
5 40 7 Squamous cell II P2
6 140 4 Squamous cell I P3
71 1 4 7S q u a m o u s  c e l l I I I P 3
8 3 31 7S q u a m o u s  c e l l I I P 2
9 10 - Squamous cell I P2
10 13 - Squamous cell I P2
11 4 35 Squamous cell I P1
12 14 8 Squamous cell II P2
13 85 0 Transitional cell III P2
14 105 0 Squamous cell II P3
15 100 5 Transitional cell II P2
16 70 1 Squamous cell I P3
17 28 0 Squamous cell II P2
18 270 9 Adenocarcinoma III P3
19 135 35 Squamous cell 
(verrucous type)
IP 3
20 20 0 Squamous cell III P2
21 105 8 Squamous cell II P2
22 165 0 Transitional cell II P3
Mean urine CEA in bilharzial carcinoma: 75.09 mg/ml (Standard deviation: 64.26 ng/ml)
Mean serum CEA in bilharizal carcinoma = 5.03 ng/ml (Standard deviation = 5.41 ng/ml)World Journal of Surgical Oncology 2007, 5:4 http://www.wjso.com/content/5/1/4
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cases only serum CEA levels were raised with normal uri-
nary CEA levels.
With nonmetastatic bladder carcinoma, plasma CEA lev-
els in one study were raised only in 42% of the patients,
but with the development of extravesical metastatic
spread, the incidence of raised plasma CEA values
increased to 85% [6]. On the other hand, in a case report,
CEA was elevated with the development of adenocarci-
noma in the reconstructed bladder following ileocysto-
plasty [21]. Some authors also stressed the use of plasma
CEA in assessing response to chemotherapy in advanced
bladder cancer [22]. In this series, serum CEA levels were
raised in 39% of patients with bilharzial carcinoma of the
urinary bladder and in only 10.5% of control cases. This
indicates that serum CEA is of little diagnostic value in
carcinoma of the urinary bladder although there was a sig-
nificant difference between the mean of serum CEA in
patients with carcinoma and the controls. There were no
documented cases with distant metastases but the patients
Table 3: CEA in urine and serum of the control cases.
Case No. Urine CEA (ng/ml) Serum CEA (ng/ml)
112
202
311 . 5
402
5 0.5 2.5
6 1.5 1.5
701
820 . 5
920 . 5
10 1 0.5
Mean for urine CEA in of control cases = 0.9 ng/ml (Standard deviation = 0.77 ng/ml)
Mean for serum CEA of control cases = 1.4 ng/ml (Standard deviation = 0.74 ng/ml)
Table 2: CEA in urine and serum, histopathological type, grade of malignancy and pathological stage of nonbilharzial carcinoma of the 
urinary bladder.
Case No Urine CEA (ng/ml) Serum CEA (ng/ml) Histological Type Grade Stage
12 2 8 T r a n s i t i o n a l I I I P 3
2 10 10 Transitional III P1
3 14 -- Transitional III P2
4 30 -- Transitional III P3
5 8 4 Anaplastic IV P2
6 26 3.5 Transitional III P2
7 160 2.5 Transitional III P3
81 7 3 T r a n s i t i o n a l I I I P 1
91 3 3 T r a n s i t i o n a l I I I P 2
10 3 5 Transitional III P1
11 165 0.5 Transitional III P2
12 135 0.5 Anaplastic IV P3
13 15 0.5 Transitional II P2
14 4 0.5 Transitional II P2
15 120 1 Transitional III P3
16 75 3 Transitional II P1
17 3 1 Transitional II P1
18 5 0 Squamous III P3
19 5 3 Transitional III P2
20 1 0 Transitional III P2
21 90 3 Squamous II P1
Mean for urine CEA in non-bilharzial carcinoma = 43.86 ng/ml. (Standard deviation = 55.70 ng/ml)
Mean for serum CEA in non-bilharzial carcinoma = 2.74 ng/ml. (Standard deviation = 2.68 ng/ml)
Mean urine CEA in squamous cell carcinoma = 58.26 ng/ml. (Standard deviation = 42.12 ng/ml)
Mean urine CEA in transitional cell carcinoma = 50.14 ng/ml. (Standard deviation = 58.31 ng/ml)
Mean serum CEA in squamous cell carcinoma = 5.60 ng/ml. (Standard deviation = 5.41 ng/ml)
Mean serum CEA in transitional cell carcinoma = 2.37 ng/ml. (Standard deviation = 2.79 ng/mlWorld Journal of Surgical Oncology 2007, 5:4 http://www.wjso.com/content/5/1/4
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with raised serum CEA levels in this series might have
spread to the regional lymph nodes or have distant
micrometastases elsewhere in the body.
Regarding the tumor stage, some authors have found a
correlation between it and the level of CEA in urine, the
higher the stage the higher the level [3,5,23,24] However,
others found no correlation [7,10,11,19,25] In this series,
a definite relationship was found between the stage of
malignancy and the levels of urinary CEA in the urine; the
higher the stage the higher the level of CEA. On the other
hand, serum CEA was in another study found to increases
with increasing extent of cancer [3]. On the contrary, no
correlation was found in the present study [5,10,11]. In
this series, no relationship could be detected between the
stage of malignancy and the level of serum CEA.
Many authors found no correlation between the grade of
malignancy and urine CEA levels [1,5-7,19,25,26]. How-
ever, others have advocated that the less differentiated the
tumor, the higher is the level of CEA in the urine [3]. In
this series, no correlation was found between the urinary
CEA levels and the different grades of malignancy.
The levels of urinary CEA in this series in bilharzial carci-
noma were higher than the levels in nonbilharzial carci-
noma, though the difference was insignificant (P > 0.05
and < 0.10). This difference may be attributed to the asso-
ciated chronic cystitis which is always present in bilharzial
carcinoma as chronically stimulated urothelium forms
CEA at an increased rate, and therefore increased release
of CEA in the urine occurs [5,27]. It was also found by
some authors that in premalignant bilharzial lesions, CEA
in the urine reached levels as high as those encountered in
frank bladder malignancy [8]. These premalignant lesions
in association with bilharzial carcinoma may lead to this
increase in CEA production. The other proposed cause for
this difference is the tumor mass, as bilharzial carcinoma
tends to be more bulky [15], and according to some
authors, CEA in the urine increases with the increase in
the size of the tumor [6,19,23,26]. This difference is not
due to the histopathological difference between bilharzial
and nonbilharzial carcinoma as no difference could be
detected between urinary CEA in squamous cells carci-
noma and transitional cell carcinoma in this series.
Conclusion
Estimation of urine CEA can be useful in the early detec-
tion of carcinoma of the urinary bladder among high-risk
people, particularly if provoked by bilharziasis. It adds
more data to the staging of tumors, and hence to the prog-
nosis after treatment.
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